AIM ImmunoTech Engages in Insightful Fireside Chat Event
OCALA, Fla. — AIM ImmunoTech Inc. (NYSE American: AIM) has announced that its Chief Executive Officer, Thomas K. Equels, will be part of an engaging moderated fireside chat on Thursday, December 4. This event is part of the Virtual Investor Closing Bell Series and is set to commence at 4:00 PM ET.
Focus on Clinical Strategies
The chat will delve into AIM's clinical and regulatory strategies regarding its promising lead drug, Ampligen. A significant feature of the discussion will be the ongoing DURIPANC clinical trial. This trial, conducted in partnership with AstraZeneca, is exploring the combination therapy of Ampligen and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor, Imfinzi (durvalumab), in treating metastatic pancreatic cancer.
Collaborative Endeavors
Equels will highlight the collaboration with AstraZeneca and the significance of Ampligen within the trial. Additionally, the conversation will cover the findings from a recent Phase 2 clinical trial conducted with Merck Sharp & Dohme LLC, where Ampligen was combined with Merck’s Keytruda (pembrolizumab) in advanced recurrent ovarian cancer treatment. The results indicated that this combination approach not only demonstrated clinical benefits but was also well-tolerated among patients.
Recent Presentations
Notably, an abstract detailing the findings from this clinical trial was recently showcased at a prominent meeting, emphasizing AIM's commitment to advancing cancer treatment through innovative therapies.
Engagement Opportunities with the Audience
Before the event, attendees and interested individuals are encouraged to submit questions via email to aim@jtcir.com. During the session, Equels will address as many questions as time permits, fostering a direct line of communication between the company and its audience.
Webcasting the Event
The fireside chat will be accessible to a wider audience through a live video webcast on the Events page of AIM ImmunoTech's website, aimimmuno.com. For those who cannot attend in real-time, a replay of the webcast will be available approximately two hours after the live presentation, remaining accessible for 90 days.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. specializes in immunotherapy-focused pharmaceuticals, endeavoring to evolve the treatment of various cancers, immune disorders, and viral diseases, including challenges posed by COVID-19. The company’s flagship product, Ampligen, is distinguished as a first-in-class investigational drug. It acts as a dsRNA and selective TLR3 agonist, displaying broad efficacy in clinical trials aimed at globally significant diseases.
To explore more about AIM ImmunoTech’s innovative endeavors and ongoing trials, please visit aimimmuno.com. Engage with the company on various platforms including X, LinkedIn, and Facebook.
Frequently Asked Questions
What will AIM ImmunoTech discuss during the fireside chat?
The discussion will cover AIM's clinical strategies, especially focusing on their lead drug Ampligen and findings from significant clinical trials.
Who is the speaker at the event?
Thomas K. Equels, the CEO of AIM ImmunoTech, will be the keynote speaker during the session.
How can the audience participate in the chat?
Interested parties can submit their questions in advance to the provided email, and Equels will address them during the chat.
Where can I view the webcast?
The webcast will be available on AIM's official website, allowing access to both live and recorded sessions for later viewing.
What is Ampligen?
Ampligen is AIM’s lead investigational drug, a first-in-class treatment known for its therapeutic potential against various cancers and immune disorders.
